...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Looks like 0 participation in warrant incentive imo - answer to my email...

sidebar - If you are anticipating exciting news in the not so distant future and you have confidence in Don and the BOD as you stated "you are correct in repetitive" to wideout, why don't you give Don and the BOD time to deliver a solution to you. We don't know how much was raised in the warrant repricing or any other options they are pursuing at this time. 

You state that the company does not have the ability to raise funding for a bolt-on or another P3, maybe, maybe not. What's interesting though is that you mention this after Don very clearly stated that RVX would not be doing a bolt-on or P3 on their own. This was stated at the AGM, yet it continues to be brought up, why? A well-structured partnership may be our best option but you totally dismiss this, why? You state that a Buy Out now is our only real option. Although I agree that it may be a great option for us the shareholders right now, it may not be the best option for either the current shareholders or BP at this time.

If a BP were to buy us today, we may get $200 million to $4 billion and then they could put another $100 to $500 million into a bolt-on or new P3 to have a chance of having a new product and they could fly or die on the decision they make today. As near as I can tell from past experience after being in this stock since about 2007, BP has deliberately taken steps to reduce their R&D risk by letting companies like RVX develop drugs to the point of massive de-risking and then paying larger amounts for potential drugs that are much closer to getting to market. In the example above let’s say $2 billion is the numbers that is satisfactory to both parties and we can also guess that a new P3 would cost about $300 million for an all-in cost of $2.3 billion and 3 to 4 years before a drug would start generating revenue, if they have a successful trial. Wouldn't it be better for a BP to make a deal to fund a new P3 today for $300 million and get a first right of refusal to buy a drug, or company only if they had a successful trial? Even if they paid $2 to $5 billion more it would still be a better decision for the BOD of that BP because they would only be spending real dollars on surety and not the speculation of maybe passing another trial. Remember this, epigenetics is brand new medical science outside of oncology. That is a big risk for a BP all on its own as well as for us, the current shareholders.

Bringing this to a wrap; At the AGM it was said that RVX would be meeting with the FDA on Nov 13, on Nov 18ths web call it was stated that we would hear something about an application for something with the FDA in 90 to 120 days. This 90 to 120-day time frame was repeated again in the Dec06 web call. Doing the math that would put mid Feb to mid March at about the time we would hear something about whatever was applied for. We are not even at the end of Jan, at least 2 weeks before the earliest time in the frame and you seem to be saying the RVX world be coming to an end unless they get Bought Out now as their only option.

Based on the history of Don and the BOD IMO it may be best to let them play this out until the end of March or so before you start to lose your stuff. You have already stated that you have confidence in Don and the BOD, why not give them enough leash and time within their stated time frame, plus a little because it’s RVX, to do what they already have in the works.

We are going to either fly or die. If you don't believe they are going to fly please make the adjustment to your portfolio and stop saying the only option you see. There are a number of options. Some are better for shareholders than others today, but not necessarily better for tomorrow. There are a number of irons in the fire right now for the company, let them play out.

All IMO, dyodd

 

tada

 

Share
New Message
Please login to post a reply